Global U.S. Urea Cycle Disorders Treatment Market
Market Overview:
The urea cycle disorders (UCD) treatment market involves drugs and supplements
prescribed for managing urea cycle disorders. Urea cycle disorders are a group
of rare, inherited genetic conditions that affect the body's ability to remove
ammonia from the bloodstream. Elevated levels of ammonia in the bloodstream,
known as hyperammonemia, can damage the brain and be life-threatening. The
treatment includes sodium phenylbutyrate, glycerol phenylbutyrate, sodium
benzoate and arginine hydrochloride supplements which help eliminate ammonia
from the body. Urea cycle disorders require lifelong management to prevent
intellectual disability and other medical complications.
The Global urea cycle disorders treatment market is
estimated to be valued at US$ 587.52 Mn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period
2024 to 2030.
Key Takeaways:
Key players: Key players operating in the U.S. urea cycle disorders treatment
market are Kawasumi Laboratories Inc., Blood Purification Technologies Inc.,
AWAK Technologies Pte. Ltd, Triomed AB, Asahi Kasei Medical Vo. Ltd, US Kidney
Research Corporation, Merit Medical Systems, NIPRO Medical Corporation,
Fresenius SE & Co. KGaA. These players are focusing on new product launches
and strategic collaborations to strengthen their market position.
Key opportunities: Increased awareness about early diagnosis and available
treatment options present lucrative opportunities for players in this market.
Technological advancements in drugs that effectively manage ammonia levels also
offer growth prospects over the forecast period.
Global expansion: Major players are expanding Global
U.S. Urea Cycle Disorders Treatment Market by strengthening their
distribution networks across countries. The availability of generic drugs is
also driving the adoption of UCD treatments in developing nations. Regulatory
approvals for new drug candidates will further aid international expansion
plans of companies.
Market drivers: Rising incidence of genetic urea cycle disorders primarily
drives demand. According to the UCD Partners, every year around 900 to 1000
babies are born with urea cycle disorders in the U.S. The development of novel
drugs with minimal side effects also spurs market growth.
Market restraints: High costs of urea cycle disorder medications pose
limitations on market revenues. Adherence to lifelong medication regimens and
lifestyle changes also restrain patient compliance. Lack of awareness in remote
areas challenges early diagnosis and timely intervention.
Segment Analysis
The U.S. urea cycle disorders treatment market is dominated by the drugs
segment. Drugs used to treat urea cycle disorders help remove toxic ammonia
from the blood by replacing missing enzymes or substances needed for the urea
cycle to function properly. Some of the commonly prescribed drugs include
sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, and sodium
phenylacetate. Among these, sodium phenylbutyrate is the most prescribed drug
as it helps manage elevated levels of ammonia by facilitating waste removal
through an alternative pathway.
Global Analysis
The North America region holds the largest share in the global urea cycle
disorders treatment market owing to the presence of established healthcare
infrastructure and strong reimbursement policies in countries like the U.S. and
Canada. The rising awareness about early diagnosis of urea cycle disorders and
availability of advanced treatment options drive the market growth. The Asia
Pacific region is expected to witness fastest growth during the forecast
period. This is attributed to growing healthcare spending, increasing patient
population, and rising medical tourism in countries like India, China, and
Japan.
Get More
Insights On This Topic: U.S.
Urea Cycle Disorders Treatment Market